| Original language | English |
|---|---|
| Pages (from-to) | 1631-1637 |
| Number of pages | 7 |
| Journal | Osteoporosis international |
| Volume | 33 |
| Issue number | 8 |
| Early online date | 2022 |
| DOIs | |
| Publication status | Published - Aug 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Osteoporosis international, Vol. 33, No. 8, 08.2022, p. 1631-1637.
Research output: Contribution to journal › Editorial › Academic › peer-review
TY - JOUR
T1 - Population screening for fracture risk in postmenopausal women — a logical step in reducing the osteoporotic fracture burden?
AU - McCloskey, E. V.
AU - Chotiyarnwong, P.
AU - Harvey, N. C.
AU - Lorentzon, M.
AU - Kanis, J. A.
AU - International Osteoporosis Foundation Epidemiology/Quality of Life Working Group
AU - Prieto-Alhambra, D.
AU - Abrahamsen, B.
AU - Adachi, J. D.
AU - Borgström, F.
AU - Bruyere, O.
AU - Carey, J. J.
AU - Clark, P.
AU - Cooper, C.
AU - Curtis, E. M.
AU - Dennison, E.
AU - Diaz-Curiel, M.
AU - Dimai, H. P.
AU - Grigorie, D.
AU - Hiligsmann, M.
AU - Khashayar, P.
AU - Lewiecki, E. M.
AU - Lips, P.
AU - Lorenc, R. S.
AU - Ortolani, S.
AU - Papaioannou, A.
AU - Silverman, S.
AU - Sosa, M.
AU - Szulc, P.
AU - Ward, K.
AU - Yoshimura, N.
N1 - Funding Information: E.M.C. reports lecture fees and travel support from Eli Lilly, Pfizer and UCB, outside the submitted work. Funding Information: D.P-A. reports institutional receipt of speaker fees from AMGEN and UCB Biopharma; consultancy fees from UCB Biopharma; research grants from UCB, Amgen, and Les Laboratoires Servier, all outside of the submitted work. Funding Information: B.A. reports grants and personal fees from UCB, personal fees from Amgen, grants from Novartis, grants and personal fees from Pharma-cosmos, grants and personal fees from Kyowa Kirin, personal fees for Gedeon Richter outside the submitted work. BA also serves on the NovoNordisk Foundation Grants Committee on Endocrinology and Metabolism. Funding Information: E.V.M reports consultant/advisor fees, speaker honoraria and or, research funding from AgNovos, Amgen, Consilient Healthcare, Fresenius Kabi, Gedeon Richter, Internis, Lilly, Novartis, ObsEva, Synexus, and UCB, all outside the submitted work.
PY - 2022/8
Y1 - 2022/8
UR - http://www.scopus.com/inward/record.url?scp=85133228403&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s00198-022-06419-6
DO - https://doi.org/10.1007/s00198-022-06419-6
M3 - Editorial
C2 - 35763073
SN - 0937-941X
VL - 33
SP - 1631
EP - 1637
JO - Osteoporosis international
JF - Osteoporosis international
IS - 8
ER -